Hospital Readmissions Among Children With H1N1 Infl uenza Infection (Continued on last page)
The novel pandemic infl uenza A H1N1 virus (infl uenza subtype, hemagglutinin1, neuraminidase 1; hereafter referred to as H1N1), fi rst appeared in the spring of 2009. [1] [2] [3] The resultant burden on emergency departments and inpatient wards stretched institutions caring for children. 4 Few data exist examining hospital readmission for children with H1N1 or infl uenza in general. Data regarding the use of oseltamivir, an inhibitor of the infl uenza enzyme neuraminidase, 5 have been confl icting with some studies showing shortened duration and severity of seasonal infl uenza infection in adults and children including patients with high-risk conditions. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, 2 recent meta-analyses have suggested that although oseltamivir decreases the duration of symptoms or the time to fi rst alleviation of symptoms, it did not decrease the rate of provider-diagnosed pneumonia or hospitalization. 17, 18 These new fi ndings arise in part from the fact that 9 randomized controlled trials sponsored by manufacturers had not previously been published in full even though patients agreed to be subjects in a study of what was an experimental medication. 17 It is unknown whether oseltamivir may affect long-term complications such as superinfections and exacerbations of underlying conditions including asthma. [19] [20] [21] Data on readmissions for children hospitalized with infl uenza are limited. Such data may be helpful in planning for future epidemics and pandemics. The primary objective of this study was to determine the rate of hospital readmission at 3-, 7-, and 30-day intervals after discharge among patients with complications of infl uenza during their index hospitalization and for children with uncomplicated index hospitalization. A secondary objective of this study was to determine the association between oseltamivir administration during the index hospitalization and readmission among children with complicated and uncomplicated infl uenza during the H1N1 pandemic. We hypothesized that hospitalized children treated with oseltamivir would experience fewer subsequent readmissions. Finally, we compared readmission rates between children with uncomplicated and complicated index infl uenza hospitalizations.
METHODS

Study Design and Data Source
Data for this multicenter retrospective cohort study were obtained from the Pediatric Health Information System, which contained demographic and resource-utilization data from 42 freestanding children's hospitals. Participating hospitals are located in noncompeting markets of 27 states plus the District of Columbia and account for 20% of all pediatric hospitalizations in the United States. Billing data include medications, radiologic imaging studies, laboratory tests, ICU charges, and diagnoses. Data are deidentifi ed before inclusion in the database, but encrypted medical record numbers allow for track ing individual patients across admissions. The Children's Hospital Association (Overland Park, KS) and par ticipating hospitals jointly ensure data quality as described previously. 22, 23 In accordance with the Common Rule (45 CFR 46.102(f)) and the policies of Cincinnati Children's Hospital Medical Center Institutional Review Board, this research, using a deidentifi ed data set, was not considered human subjects research.
Study Participants
Patients ≤18 years of age hospitalized with infl uenza between May 2 and December 11, 2009 (Morbidity and Mortality Weekly Report weeks 17-48) at participating hospitals were eligible for inclusion. Because oseltamivir was the predominant antiviral agent used during the H1N1 pandemic period (only 52 patients received antiviral agents other than oseltamivir), patients receiving other antiviral agents either alone or in combination with oseltamivir were excluded (Fig 1) . www.hospitalpediatrics.org
Study Defi nitions
Children with infl uenza were identifi ed by the presence of an Internation al Classifi cation of Diseases, Ninth Revision, Clinical Modifi cation (ICD-9-CM), discharge diagnosis code 487 (infl uenza) or 488 (infl uenza due to certain identifi ed infl uenza viruses) in any discharge diagnosis fi eld. To maximize the likelihood that only children with novel H1N1 were included, we defi ned our study period to coincide with the periods when novel H1N1 was the predominant circulating virus. Therefore, the start and end dates were chosen to include the fi rst and last 2-week periods when at least 10% of surveillance samples tested positive for infl uenza viruses in the United States. World Health Organization-collaborating laboratories and the National Respiratory and Enteric Virus Surveillance System. The start date also coincided with the fi rst week that 2009 Infl uenza A H1N1 was the predominant strain isolated in World Health Organization/ National Respiratory and Enteric Virus Surveillance System laboratories. 24 During this period, ∼1.0% of samples tested positive for seasonal infl uenza viruses, H3N2 seasonal infl uenza virus or infl uenza B.
A priori, through consensus of the study team of pediatric hospital medi cine, critical care, infectious dis eases, and emergency medicine physicians, we constructed 2 lists of diagnoses: complications of infl uenza and conditions precipitated by infl uenza (Appendix). Complications of influenza included conditions caused directly by the infl uenza virus (eg, encephalopathy) as well as illnesses that oc curred as a result of preceding influ enza infection (eg, bacterial pneumonia).
Conditions precipitated by infl uenza included underlying diagnoses that were exacerbated by infl uenza infection (eg, asthma). To compile these 2 lists, the study team drew on sev er al sources: the Electronic Surveil lance System for the Early Notifi cation of CommunityBased Epidemics (ES SENCE) II list of ICD-9-CM discharge diagnosis for infl uenza syndromic surveillance in the military, validated in the 2009 H1N1 infl uenza pandemic, [25] [26] [27] [28] and pediatricspecifi c lists of infl uenza-related diagnoses, which remain unvalidated. [29] [30] [31] [32] Chronic comorbid conditions (CCCs; eg, malignancy) were identified using a previously reported classifi cation method. 33 For patients with multiple readmissions, only data from the index rehospitalization were included. However, patients with >1 ICD-9 code for the index readmission may have been coded as having both a condition precipitated by influenza and an influenza-related complication.
Main Outcome Measures
Patients were divided into 2 groups: those who had an uncomplicated index hospitalization and those who experienced an infl uenza-related complication or condition precipitated by infl uenza during their initial hospitalization. The primary outcomes were all-cause readmissions within 3, 7, and 30 days of the discharge from the index hospitalization as well as readmission within 3, 7, and 30 days with a complication of infl uenza or a condition precipitated by infl uenza. This time frame was chosen to identify short-term rehospitalizations as well as an extended period to identify complications that developed subsequent to the index visit. Secondary outcome was the association of oseltamivir treatment with readmission at 3, 7, and 30 days.
Statistical Analysis
Analyses were performed on each group separately, and then readmission rates were compared between the 2 groups. Variables were summarized using frequencies and percentages for categorical variables and median, interquartile range (IQR), and range values for continuous variables. Demographic characteristics and outcomes were compared by using χ 2 tests for categorical variables.
Bivariate analyses examined the association between treatment group and 30-day readmissions in the both study populations (patients with uncomplicated and complicated index hospitalizations), as well as in the following subgroups: those in the ICU during the index hospitalization, those with CCCs, those readmitted for a complication of infl uenza, and those readmitted for a condition precipitated by infl uenza. Multivariable logistic regression was performed to measure the association between treatment group and 3-, 7-, and 30-day readmission using primary readmission diagnosis, adjusting for gender, race, payor status, and age. To account for severity of illness, we adjusted for the presence of a CCC and for the LOS and requirement for ICU admission during the index hospitaliza tion. Generalized estimating equations ac counted for clustering of outcomes within hospitals. Odds ratios and 95% confi dence intervals were reported to convey the magnitude and the precision of the estimate of effect. Analyses were performed by using SAS version 9.2 (SAS Institute, Cary, NC). A 2-tailed P < .05 was considered statistically signifi cant.
RESULTS
During the study period, 8899 children were included in the analysis, of whom 6162 patients (69.2%) had no condition precipitated by infl uenza or infl uenza-related complications during index hospitalization.
Of the 6162 patients with uncomplicated infl uenza, 3808 (61.8%) received oseltamivir (Fig 1) . The median age was 4.9 years (IQR 1.3-10.0 years). Statistically signifi cant differences occurred by treatment group in race, payor status, presence of a (CCC), and age (Table 1) . CCCs were more prevalent among children receiving oseltamivir; however, among individuals with CCCs only the presence of a hematologic/immunologic CCC was signifi cantly greater in the oseltamivir group. The median index hospital LOS for all patients was 2 days (IQR 1-3 days) with no difference found by treatment group. For all patients, 9.4% were admitted to the ICU during the index hospitalization.
There were 2737 children with an infl uenza-related complications or conditions precipitated by infl uenza during the index hospitalization of whom 1055 patients (38.5%) received oseltamivir. Differences occurred by treatment groups in gender, race, payor status, presence of a CCC, age, and LOS (Table 1) . Table 2 shows readmission rates at 3-, 7-, and 30-day intervals for all children with infl uenza during index (Table 2) .
Readmission rates among patients with infl uenza-related complications or conditions precipitated by infl uenza at index hospitalization were high with all-cause readmission rates at 3, 7, and 30 days of 4.3%, 5.8%, and 10.2%, respectively ( Table 2 ). The only difference between treatment groups for children with complications of infl uenza at index hospitalization was that there was a lower readmission rate at 30 days in children treated with oseltamivir for readmissions due to infl uenza-related complications and for patients who were admitted to the ICU during index hospitalization.
The most common infl uenza-related complications resulting in readmission were primarily respiratory in nature, and the most common condition precipitated by infl uenza was asthma exacerbation (Table 3 ).
In the multivariable analysis, oseltamivir receipt was not associated with changes in 3-, 7-, or 30-day readmission in all children with initially uncomplicated infl uenza or in subgroups readmitted for influenza-related com plications and condition precipitated by infl uenza (Table 4) . However, among children who experienced complicated index hospitalizations, patients who received oseltamivir had a decreased rate of all-cause 3-, 7-and 30-day readmissions (Table 4) . Readmissions due to infl uenza-related complications were lower at all 3 time points in children who received oseltamivir. The only difference by treatment group in children readmitted with conditions precipitated by infl uenza occurred at 3 days.
When adjusted for ICU admission during index hospitalization, gender, race, payor, age, LOS during index hospitalization, and the presence of a CCC patients with infl uenza-related complications or conditions precipitated by infl uenza had signifi cantly lower all-cause readmission at 7 and 30 days compared with those with www.hospitalpediatrics.org uncomplicated index hospitalizations (Table 5) . However, patients with complicated index hospitalizations had greater readmissions due to infl uenzarelated complications and conditions precipitated by infl uenza at 3, 7, and 30 days.
DISCUSSION
In this study, children admitted with infl uenza were divided into 2 groups by whether they had complications of infl uenza during their index hospitalization. Children in the group with uncomplicated infl uenza had low rates of readmission, whereas those in the group with complications of infl uenza had a much higher rate or readmissions within 30 days. Among patients with uncomplicated infl uenza, 54.6% received oseltamivir during their index hospitalization, and only 38.5% of Adjusted for ICU admission during index hospitalization, gender, race, payor, age, LOS during index hospitalization, and the presence of any chronic comorbid condition. Overall models additionally adjusted for Oseltamivir receipt. CI, confi dence interval; NE, not estimable; OR, odds ratio. * P < .05. ** P < .01. *** P < .001.
children with complicated infections received oseltamivir. In this cohort of children hospitalized with infl uenza virus during the H1N1 pandemic and discharged without a complication of infl uenza during the index admission, there were no differences in the 3-, 7-, or 30-day adjusted readmission rates according to whether patients had received oseltamivir during index hospitalization. However, in the unadjusted analysis among patients who experienced a complication due to infl uenza during the index hospitalization, oseltamivir was associated with lower odds of patients with readmissions due to infl uenza-related complications and for those who experienced ICU admission at index hospitalization.
In the adjusted analysis among children with complicated index infl uenza admissions 3-, 7-, and 30-day all-cause readmissions were lower than in patients who received oseltam ivir compared with those not treated. When adjusted for demographic differences and severity of illness, allcause readmissions were lower in the children who had complex index hospitalization compared with those with uncomplicated index infections but readmissions for infl uenza-related complications, and conditions precipitated by infl uenza were signifi cantly higher in the group with complicated index admissions.
Hospital readmission is a complex process that depends on patient health status, hospital care, and factors external to the patient and quality of hospital care. 34 Readmissions after infl uenza infections have not been well described, although other complications of pandemic H1N1 infl uenza, such as asthma exacerbations, have been noted previously. 19, 20, 35 One study that evaluated readmission in children with complicated pneumonia found that children with infl uenza coinfection had longer LOS and a trend toward higher mortality, but a lower 14-day hospital readmission rate. 36 In this cohort, the most common infl uenza-related complications and conditions precipitated by infl uenza were respiratory in nature (infections and asthma, respectively). The 30-day readmission rate of 4.7% in children with uncomplicated index hospitalization accorded with the 30-day readmission rate in a large all-diagnosis cohort of patients discharged from children's hospitals in 24 American states (4.8%), suggesting no increase in disease burden in children after infl uenza infection during the H1N1 pandemic period compared with children hospitalized with other illnesses. 37 The 30-day readmission rate among patients with uncomplicated infl uenza was highest for children with underlying complex chronic condition, consistent with previous fi ndings. 37, 38 Patients who suffered a complication of infl uenza during the index hospitalization had a signifi cantly higher unadjusted 30-day readmission rate (10.3%) for all-cause readmissions, as well as for infl uenza-related complications or conditions precipitated by infl uenza, than patients who had uncomplicated infections during index admission.
Surprisingly, in the adjusted analysis, all-cause 30-day readmission was lower in the group with complicated index infl uenza course than those with uncomplicated index hospitalization, even though readmissions were higher for infl uenza-related complications or conditions precipitated by infl uenza in the group with complicated infl uenza. These data may refl ect the importance of underlying conditions in children who have complicated index infl uenza admissions. Furthermore, it appears that complications of infl uenza remain an ongoing concern in this population even after discharge.
The primary goal of therapy once infection is established should be minimizing the extent of disease and preventing disease complications. The effi cacy of oseltamivir has been called into question in recent studies because of reporting bias. 17, 18, 35 The 2 recent meta-analyses of oseltamivir use in adults also noted bias due to suppression of data and showed oseltamivir decreased the duration of symptoms by <1 day but did not decrease hospitalizations or clinician-diagnosed pneumonias. 17, 18 In children, oseltamivir appeared to decrease symptom duration but had no effect on hospitalizations. 18 In this study, oseltamivir use during the index hospitalization was not associated with subsequent change in 30-day readmissions in children with uncomplicated initial hospitalization, but in children with complicated initial hospitalization, odds of readmission were higher in untreated patients. However, a minority of children in the complicated group (38.5%) received oseltamivir in contrast to children with uncomplicated index course (54.6%). The Centers for Disease Control and Prevention did alter its guidelines in September 2009 (midway through our study period), although the recommendation to treat hospitalized children remained unchanged. 39 Still, it is unclear why the rate of administration in this group was low. It is possible that patients had longer duration of symptoms before admission and clinicians thought oseltamivir would be relatively ineffective, so they did not treat; however, we do not have data on duration of symptoms before admission. Because a minority of patients in the complicated www.hospitalpediatrics.org group received oseltamivir, treatment may have been a proxy for other differences in hospital care. Alternatively, the lower rates of readmissions among the children with complicated admission suggest oseltamivir may have a different effect on children with complicated infl uenza disease, infl uencing readmission rates. This fi nding needs to be repeated. This study has several limitations. First, although there was no effect of oseltamivir in the patients with uncomplicated infl uenza, the effect size may be so small as to be undetectable. The diagnoses that we used to defi ne complications of infl uenza were arrived at using the validated ESSENCE II list of ICD-9-CM list of discharge diagnoses used in the military for infl uenza surveillance and pediatric-specifi c lists that remain unvalidated but tried to use well-described complications of infl uenza. 40 Unmeasured confounding or residual confounding by indication for oseltamivir therapy may occur. We adjusted for several factors associated with greater severity of illness during the index hospitalization, including ICU admission and LOS during index hospitalization, to minimize the impact of such confounding. Furthermore, we did not control for timing of oseltamivir dose or for duration of illness before hospitalization or receipt of oseltamivir before admission.
Previous studies suggest that oseltamivir appears less effective at limiting infl uenza complications when given later in the infectious course. 7, 19 We were unable to assess the duration of therapy in these patient. However, these data refl ect care provided during the pandemic and so represent the effect of the common practice of treating with oseltamivir. Oseltamivir receipt could only be determined during the hospitalization, so patients who received a complete course of oseltamivir before or after their index hospitalization would have been classifi ed as not having received oseltamivir. Our inability to account for prehospital oseltamivir would alter our assessment of the infl uence of oseltamivir in preventing H1N1 infl uenza-associated readmissions. Additionally, late administration of oseltamivir (ie, oseltamivir prescribed after discharge) may limit its ability to prevent long-term complications of H1N1. Such late prescribing would not meaningfully affect our study conclusions. Patients may have been started on oseltamivir before the results of the infl uenza test and then discharged before obtaining the result. This would bias the results toward null because this scenario would be more likely in uncomplicated patients with shorter LOS. Also, we could not determine whether patients received a full course of oseltamivir. Incomplete courses of oseltamivir would cause us to underestimate the potential benefi t of oseltamivir. Although the positive predictive value of ICD-9-CM codes for seasonal infl uenza is high, ∼88%, 32 the accuracy of ICD-9-CM codes for novel H1N1 infl uenza is not known. Additionally, although the ESSENCE II ICD-9-CM codes have been validated for H1N1 infl uenza, other codes used to identify infl uenza complications have not previously been validated. The resulting misclassifi cation, although likely minimal, would bias our results toward fi nding no difference. We were unable to examine hospital course and thus identify possible premature discharge. However, the low rate of readmission within 3 days (2%) makes the possibility of early discharge relatively small. Finally, we could not be certain that readmissions were casually related to the initial H1N1 infection, and thus we may have overestimated readmissions for both treated and untreated patients.
CONCLUSIONS
Readmissions after discharge for uncomplicated infl uenza are relatively uncommon, whereas readmissions after complicated index hospitalization with infl uenza are signifi cantly more frequent. Pneumonia/empyema, acute respiratory failure, sepsis, and asthma exacerbation account for most readmissions. Treatment with oseltamivir during the index hospitalization was not associated with fewer 30-day readmissions among those discharged with uncomplicated H1N1 infl uenza infection but appears to be associated with lower odds of readmission rates in children who experienced complications of infl uenza at initial hospitalization.
